CureVac N.V. - Ordinary Shares (NQ:CVAC)

4.660 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Earnings Scheduled For April 10, 2025 ↗

April 10, 2025

Via Benzinga

Insights Ahead: CureVac's Quarterly Earnings ↗

April 09, 2025

Via Benzinga

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

April 08, 2025

Via ACCESS Newswire

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

April 07, 2025

Via ACCESS Newswire

Traders are paying attention to the gapping stocks in Friday's session. ↗

March 28, 2025

Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators

February 18, 2025

Via ACCESS Newswire

Why CureVac (CVAC) Stock Is Moving ↗

January 08, 2025

Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains driven by rising concerns over U.S. respiratory illnesses.

Via Benzinga

Top movers in Friday's pre-market session ↗

March 28, 2025

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday ↗

March 28, 2025

Via Benzinga

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps ↗

March 28, 2025

CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in July 2025.

Via Benzinga

Topics Intellectual Property

Wondering what's happening in today's after-hours session? ↗

March 27, 2025

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

November 12, 2024

Via ACCESSWIRE

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

March 27, 2025

Via ACCESS Newswire

Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch ↗

February 10, 2025

A Nevada dairy worker who initially tested positive for bird flu is currently experiencing mild symptoms, including "pink eye."

Via Benzinga

Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads ↗

January 24, 2025

As the bird flu virus continues to spread through the United States, the Trump administration on Tuesday ordered all communications from the Centers for Disease Control and Prevention to stop.

Via Benzinga

Topics Government

Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine ↗

January 21, 2025

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus.

Via Benzinga

Insights into CureVac's Upcoming Earnings ↗

November 11, 2024

Via Benzinga

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

November 04, 2024

Via ACCESSWIRE

Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing ↗

January 16, 2025

The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu virus within 24 hours.

Via Benzinga

Why CureVac (CVAC) Shares Are Volatile ↗

January 10, 2025

CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following the U.S.'s first human death from H5N1 bird flu.

Via Benzinga

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies ↗

January 08, 2025

Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.

Via Benzinga

Topics ETFs

US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally ↗

January 07, 2025

The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute respiratory illnesses...

Via Benzinga

Why CureVac (CVAC) Stock Is Rising ↗

January 06, 2025

Shares of CureVac are trading higher by 15% during Monday's session. The stock is gaining following a CDC report highlighting a significant increase in acute respiratory illnesses nationwide.

Via Benzinga

2 Small-Cap Stocks Set to Shine in a Bull Market

December 16, 2024

Small-cap growth-orientated stocks like HTCR and CVAC often outperform during bullish markets due to their sensitivity to improving economic conditions.

Via MarketBeat

Topics ETFs

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

November 07, 2024

Via ACCESSWIRE

CureVac to Present at the 12th International mRNA Health Conference

November 04, 2024

Via ACCESSWIRE

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

October 28, 2024

Via ACCESSWIRE

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

September 13, 2024

Via ACCESSWIRE

GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine ↗

September 12, 2024

GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.